Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
作者： S Nagalla , L Thomson , Y Oppong , B Bachman , I Chervoneva
DOI: 10.1111/CTS.12398
关键词:
摘要: It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 subjects received 5 mg every h. Three h after fifth dose, or saline were infused. Serial blood samples assessed for using PPP-reagent and low, anti-Xa, PT, PTT assays. Geometric mean ratio calculated at 30 min postinfusion, 24, 48, 72 Peak 76% higher postinfusion 4F-PCC (p = 0.025). The difference declined 24% 24 resolved by 48 Other parameters also partially normalized. There no between anti-Xa assessment 30 min later time points.
jefferson.edu
core.ac.uk
elsevier.com
sci-hub.se 参考文章(17)
Ramesh Grandhi, W. Christopher Newman, Xiaoran Zhang, Gillian Harrison, Colleen Moran, David O. Okonkwo, Andrew F. Ducruet, Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors World Neurosurgery. ,vol. 84, pp. 1956- 1961 ,(2015) , 10.1016/J.WNEU.2015.08.042
W. H. Dzik, Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. Journal of Thrombosis and Haemostasis. ,vol. 13, ,(2015) , 10.1111/JTH.12949
Y. W. Cheung, S. Barco, B. A. Hutten, J. C. M. Meijers, S. Middeldorp, M. Coppens, In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. Journal of Thrombosis and Haemostasis. ,vol. 13, pp. 1799- 1805 ,(2015) , 10.1111/JTH.13115
Michael G. Kenward, James H. Roger, Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood Biometrics. ,vol. 53, pp. 983- 997 ,(1997) , 10.2307/2533558
Eva Herzog, Franz Kaspereit, Wilfried Krege, Jochen Mueller-Cohrs, Baerbel Doerr, Peter Niebl, Gerhard Dickneite, Correlation of Coagulation Markers and 4F-PCC-Mediated Reversal of Rivaroxaban in a Rabbit Model of Acute Bleeding Thrombosis Research. ,vol. 135, pp. 554- 560 ,(2015) , 10.1016/J.THROMRES.2015.01.007
Gines Escolar, Victor Fernandez-Gallego, Eduardo Arellano-Rodrigo, Jaume Roquer, Joan Carles Reverter, Victoria Veronica Sanz, Patricia Molina, Irene Lopez-Vilchez, Maribel Diaz-Ricart, Ana Maria Galan, Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood PLoS ONE. ,vol. 8, pp. e78696- ,(2013) , 10.1371/JOURNAL.PONE.0078696
A.-C. Martin, I. Gouin-Thibault, V. Siguret, A. Mordohay, C.-M. Samama, P. Gaussem, B. Le Bonniec, A. Godier, Multimodal assessment of non-specific hemostatic agents for apixaban reversal. Journal of Thrombosis and Haemostasis. ,vol. 13, pp. 426- 436 ,(2015) , 10.1111/JTH.12830
Deborah M. Siegal, Adam Cuker, Reversal of novel oral anticoagulants in patients with major bleeding Journal of Thrombosis and Thrombolysis. ,vol. 35, pp. 391- 398 ,(2013) , 10.1007/S11239-013-0885-0
Lisa M. Baumann Kreuziger, Colleen T. Morton, David J. Dries, New anticoagulants: A concise review. Journal of Trauma-injury Infection and Critical Care. ,vol. 73, pp. 983- 992 ,(2012) , 10.1097/TA.0B013E318265CF9E
Renato D Lopes, John H Alexander, Sana M Al-Khatib, Jack Ansell, Raphael Diaz, J Donald Easton, Bernard J Gersh, Christopher B Granger, Michael Hanna, John Horowitz, Elaine M Hylek, John JV McMurray, Freek WA Verheugt, Lars Wallentin, ARISTOTLE Investigators, None, Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale American Heart Journal. ,vol. 159, pp. 331- 339 ,(2010) , 10.1016/J.AHJ.2009.07.035